Drugmakers look to HDL-raising pills as next big seller

11/30/2005 | Forbes

Large pharmaceutical companies, followed closely by smaller competitors, are racing to get onto the market drugs that raise high-density lipoprotein cholesterol levels. Pfizer is betting the $800 million it invested in developing torcetrapib will lead to $1 billion in sales during its first year on the market, but Merck, Roche Holding, Novartis and Kos Pharmaceuticals are close behind.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Medical Device Reimbursement Specialist - Regional
Alcon
Fort Worth , TX
Assistant General Counsel/Senior Corporate Counsel - Healthcare Law Group
Genentech
94080, CA
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
MANAGER MEDICAL GAS COMPLIANCE AND SAFETY
Matheson Tri-Gas, Inc.
Houston, TX